Radioiodine therapy of Graves' disease and the uptake paradox

Sumeet Suresh Malapure, Anirban Mukherjee, Chandrasekar Bal

Research output: Contribution to journalArticle

Abstract

Purpose of the Study: Radioiodine (131I) therapy is approved and well-Accepted modality for the treatment of hyperthyroidism. The dosage of131I for successful treatment is based on many factors; however, an objective tool to determine the dose was missing. In a retrospective study, we found that high131I uptake values required more dose to achieve desirable results contrary to the belief. Materials and Methods: Clinically and scintigraphically proven Graves' disease patients with high131I uptake (>50%) were accrued for this study and block randomized into low-dose (Group I) and high-dose (Group II) groups. Low activity (5 mCi) was administered in Group I and higher activity (10 mCi) in Group II. The patients were followed up after 3 months with thyroid function tests to determine the outcome. Results: A total of 344 patients were analyzed at the end of 3 months, with 174 in low-dose group and 170 in high-dose group. Euthyroidism/hypothyroidism was achieved in significantly higher number of patients as compared to the low-dose group. Conclusion: The higher dose of131I is required to achieve euthyroidism/hypothyroidism in patients with high131I uptake.

Original languageEnglish
Pages (from-to)17-20
Number of pages4
JournalIndian Journal of Nuclear Medicine
Volume35
Issue number1
DOIs
Publication statusPublished - 01-01-2020
Externally publishedYes

Fingerprint

Graves Disease
Hypothyroidism
Therapeutics
Thyroid Function Tests
Hyperthyroidism
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Malapure, Sumeet Suresh ; Mukherjee, Anirban ; Bal, Chandrasekar. / Radioiodine therapy of Graves' disease and the uptake paradox. In: Indian Journal of Nuclear Medicine. 2020 ; Vol. 35, No. 1. pp. 17-20.
@article{6f0d5547359d4ea59ac0fa3b14a1fec7,
title = "Radioiodine therapy of Graves' disease and the uptake paradox",
abstract = "Purpose of the Study: Radioiodine (131I) therapy is approved and well-Accepted modality for the treatment of hyperthyroidism. The dosage of131I for successful treatment is based on many factors; however, an objective tool to determine the dose was missing. In a retrospective study, we found that high131I uptake values required more dose to achieve desirable results contrary to the belief. Materials and Methods: Clinically and scintigraphically proven Graves' disease patients with high131I uptake (>50{\%}) were accrued for this study and block randomized into low-dose (Group I) and high-dose (Group II) groups. Low activity (5 mCi) was administered in Group I and higher activity (10 mCi) in Group II. The patients were followed up after 3 months with thyroid function tests to determine the outcome. Results: A total of 344 patients were analyzed at the end of 3 months, with 174 in low-dose group and 170 in high-dose group. Euthyroidism/hypothyroidism was achieved in significantly higher number of patients as compared to the low-dose group. Conclusion: The higher dose of131I is required to achieve euthyroidism/hypothyroidism in patients with high131I uptake.",
author = "Malapure, {Sumeet Suresh} and Anirban Mukherjee and Chandrasekar Bal",
year = "2020",
month = "1",
day = "1",
doi = "10.4103/ijnm.IJNM_158_19",
language = "English",
volume = "35",
pages = "17--20",
journal = "Indian Journal of Nuclear Medicine",
issn = "0972-3919",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

Radioiodine therapy of Graves' disease and the uptake paradox. / Malapure, Sumeet Suresh; Mukherjee, Anirban; Bal, Chandrasekar.

In: Indian Journal of Nuclear Medicine, Vol. 35, No. 1, 01.01.2020, p. 17-20.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Radioiodine therapy of Graves' disease and the uptake paradox

AU - Malapure, Sumeet Suresh

AU - Mukherjee, Anirban

AU - Bal, Chandrasekar

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Purpose of the Study: Radioiodine (131I) therapy is approved and well-Accepted modality for the treatment of hyperthyroidism. The dosage of131I for successful treatment is based on many factors; however, an objective tool to determine the dose was missing. In a retrospective study, we found that high131I uptake values required more dose to achieve desirable results contrary to the belief. Materials and Methods: Clinically and scintigraphically proven Graves' disease patients with high131I uptake (>50%) were accrued for this study and block randomized into low-dose (Group I) and high-dose (Group II) groups. Low activity (5 mCi) was administered in Group I and higher activity (10 mCi) in Group II. The patients were followed up after 3 months with thyroid function tests to determine the outcome. Results: A total of 344 patients were analyzed at the end of 3 months, with 174 in low-dose group and 170 in high-dose group. Euthyroidism/hypothyroidism was achieved in significantly higher number of patients as compared to the low-dose group. Conclusion: The higher dose of131I is required to achieve euthyroidism/hypothyroidism in patients with high131I uptake.

AB - Purpose of the Study: Radioiodine (131I) therapy is approved and well-Accepted modality for the treatment of hyperthyroidism. The dosage of131I for successful treatment is based on many factors; however, an objective tool to determine the dose was missing. In a retrospective study, we found that high131I uptake values required more dose to achieve desirable results contrary to the belief. Materials and Methods: Clinically and scintigraphically proven Graves' disease patients with high131I uptake (>50%) were accrued for this study and block randomized into low-dose (Group I) and high-dose (Group II) groups. Low activity (5 mCi) was administered in Group I and higher activity (10 mCi) in Group II. The patients were followed up after 3 months with thyroid function tests to determine the outcome. Results: A total of 344 patients were analyzed at the end of 3 months, with 174 in low-dose group and 170 in high-dose group. Euthyroidism/hypothyroidism was achieved in significantly higher number of patients as compared to the low-dose group. Conclusion: The higher dose of131I is required to achieve euthyroidism/hypothyroidism in patients with high131I uptake.

UR - http://www.scopus.com/inward/record.url?scp=85077899267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077899267&partnerID=8YFLogxK

U2 - 10.4103/ijnm.IJNM_158_19

DO - 10.4103/ijnm.IJNM_158_19

M3 - Article

AN - SCOPUS:85077899267

VL - 35

SP - 17

EP - 20

JO - Indian Journal of Nuclear Medicine

JF - Indian Journal of Nuclear Medicine

SN - 0972-3919

IS - 1

ER -